211 related articles for article (PubMed ID: 18201212)
21. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
22. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
23. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
24. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
25. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
[TBL] [Abstract][Full Text] [Related]
26. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
Fritsche A; Stefan N; Hardt E; Schützenauer S; Häring H; Stumvoll M
Eur J Clin Invest; 2000 May; 30(5):411-8. PubMed ID: 10809901
[TBL] [Abstract][Full Text] [Related]
27. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
[TBL] [Abstract][Full Text] [Related]
28. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
[TBL] [Abstract][Full Text] [Related]
29. Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.
Wu L; Olverling A; Fransson L; Ortsäter H; Kappe C; Gao X; Sjöholm A
Regul Pept; 2012 Aug; 177(1-3):92-6. PubMed ID: 22587909
[TBL] [Abstract][Full Text] [Related]
30. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi G
G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
[TBL] [Abstract][Full Text] [Related]
31. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
[TBL] [Abstract][Full Text] [Related]
32. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.
Yan P; Li L; Yang M; Liu D; Liu H; Boden G; Yang G
Diabetes Res Clin Pract; 2011 Jun; 92(3):368-74. PubMed ID: 21458097
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
[TBL] [Abstract][Full Text] [Related]
34. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
Porter DW; Kerr BD; Flatt PR; Holscher C; Gault VA
Diabetes Obes Metab; 2010 Oct; 12(10):891-9. PubMed ID: 20920042
[TBL] [Abstract][Full Text] [Related]
35. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
[TBL] [Abstract][Full Text] [Related]
36. Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet.
Winzell MS; Brand CL; Wierup N; Sidelmann UG; Sundler F; Nishimura E; Ahrén B
Diabetologia; 2007 Jul; 50(7):1453-62. PubMed ID: 17479245
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
[No Abstract] [Full Text] [Related]
38. Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
Shao Y; Yuan G; Feng Y; Zhang J; Guo X
Peptides; 2014 Feb; 52():134-42. PubMed ID: 24406898
[TBL] [Abstract][Full Text] [Related]
39. Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
Polderman JA; Houweling PL; Hollmann MW; DeVries JH; Preckel B; Hermanides J
BMC Anesthesiol; 2014; 14():91. PubMed ID: 25419179
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.
Horowitz M; Vilsbøll T; Zdravkovic M; Hammer M; Madsbad S
Diabetes Obes Metab; 2008 Jul; 10(7):593-6. PubMed ID: 18435773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
